balance equationreview2020-12-31
Difference 3264000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
$236.20M
Fiscal year ended 2025-12-31Operating income
$23.50M
Fiscal year ended 2025-12-31Free cash flow
$67.70M
Fiscal year ended 2025-12-31Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.20M and net income of -$5.34M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Akebia Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.20M | $160.18M | $194.62M | $292.48M | $211.65M | $294.64M | $335.00M | $207.74M | $181.23M | $1.54M |
| Cost of revenue | $39.46M | $63.18M | $74.15M | $85.57M | $150.67M | $296.48M | $145.34M | $7.77M | Unavailable | Unavailable |
| Gross profit | $196.73M | $97.00M | $120.47M | $206.92M | $60.98M | -$1.83M | $189.66M | $199.97M | Unavailable | Unavailable |
| Operating income | $23.50M | -$50.47M | -$46.26M | -$80.78M | -$264.50M | -$377.83M | -$286.29M | -$178.16M | -$76.67M | -$136.46M |
| Net income | -$5.34M | -$69.41M | -$51.92M | -$94.23M | -$282.02M | -$384.84M | -$279.66M | -$143.59M | -$73.67M | -$135.75M |
| Research & development | $62.36M | $37.65M | $63.08M | $129.99M | $147.85M | $218.48M | $322.97M | $291.01M | $230.89M | $115.78M |
| Weighted-average diluted shares | shares 257.16M | shares 210.95M | shares 187.47M | shares 182.78M | shares 165.95M | shares 138.46M | shares 118.40M | Unavailable | Unavailable | Unavailable |
| Pretax income | -$3.72M | -$69.41M | -$51.92M | -$94.23M | -$282.02M | -$384.84M | -$286.29M | -$171.93M | -$73.67M | -$135.75M |
| Income tax expense | $1.62M | $0 | $0 | $0 | $0 | $0 | -$6.63M | -$28.34M | Unavailable | Unavailable |
| Diluted EPS | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 | $-2.78 | $-2.36 | Unavailable | Unavailable | Unavailable |
| Selling, general & administrative | $107.48M | $106.54M | $100.23M | $138.60M | $174.14M | $154.10M | $149.46M | $87.06M | $27.01M | $22.21M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $27.01M | $22.21M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $184.84M | $51.87M | $42.92M | $90.47M | $149.80M | $228.70M | $147.45M | $104.64M | $70.16M | $187.34M |
| Total assets | $376.56M | $220.67M | $241.70M | $356.05M | $529.35M | $644.14M | $771.20M | $996.54M | $364.25M | $300.22M |
| Current assets | $252.96M | $113.83M | $118.15M | $185.18M | $271.15M | $371.44M | $309.53M | $468.28M | $358.36M | $296.32M |
| Total liabilities | $343.96M | $269.86M | $272.29M | $350.82M | $455.34M | $396.52M | $376.44M | $360.61M | $241.67M | $232.10M |
| Current liabilities | $162.94M | $80.91M | $99.87M | $129.54M | $261.05M | $187.15M | $208.12M | $265.69M | $141.11M | $114.27M |
| Total equity incl. NCI | $32.61M | -$49.18M | -$30.58M | $5.23M | $74.01M | $244.35M | $392.88M | $635.93M | $122.57M | $68.12M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $15.61M | $16.24M | $15.69M | $21.57M | $36.63M | $61.02M | $116.35M | $114.24M | Unavailable | Unavailable |
| Accounts receivable | $47.03M | $34.37M | $39.29M | $40.28M | $51.58M | $26.85M | $38.86M | $16.67M | $34.22M | $33.82M |
| Goodwill | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M | $55.05M | $55.05M | $55.05M | Unavailable | Unavailable |
| Long-term debt | $48.25M | $38.69M | $17.18M | $34.08M | $0 | $96.38M | $75.80M | Unavailable | Unavailable | Unavailable |
| Accounts payable | $21.18M | $15.18M | $14.64M | $18.02M | $33.59M | $41.31M | $39.22M | $42.80M | $7.00M | $2.04M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $67.99M | -$40.66M | -$23.38M | -$73.15M | -$252.96M | -$110.39M | -$257.44M | -$97.49M | -$56.16M | $57.91M |
| Capital expenditures | $291.00K | $33.00K | $0 | $114.00K | $59.00K | $317.00K | $6.66M | $1.61M | $1.62M | $2.66M |
| Investing cash flow | -$7.93M | -$33.00K | $0 | -$114.00K | $39.94M | -$40.00M | $211.18M | $36.59M | -$177.26M | $12.70M |
| Financing cash flow | $72.93M | $49.66M | -$25.21M | $14.60M | $133.73M | $231.72M | $88.97M | $96.56M | $116.24M | $66.95M |
| Net change in cash | $132.99M | $8.97M | -$48.59M | -$58.67M | -$79.29M | $81.33M | $42.70M | $35.66M | -$117.18M | $137.56M |
| Stock-based compensation | $11.28M | $7.78M | $9.32M | $17.85M | $22.74M | $24.46M | $11.92M | $19.04M | $8.87M | $5.82M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | $1.65M | $1.93M | $2.08M | $2.24M | $899.00K | $617.00K | $296.00K |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $67.70M | -$40.69M | -$23.38M | -$73.27M | -$253.02M | -$110.70M | -$264.10M | -$99.10M | -$57.78M | $55.24M |
| Gross margin | 83.3% | 60.6% | 61.9% | 70.7% | 28.8% | -0.6% | 56.6% | 96.3% | Unavailable | Unavailable |
| Operating margin | 9.9% | -31.5% | -23.8% | -27.6% | -125.0% | -128.2% | -85.5% | -85.8% | -42.3% | -8889.9% |
| FCF margin | 28.7% | -25.4% | -12.0% | -25.1% | -119.5% | -37.6% | -78.8% | -47.7% | -31.9% | 3599.0% |
| SBC / revenue | 4.8% | 4.9% | 4.8% | 6.1% | 10.7% | 8.3% | 3.6% | 9.2% | 4.9% | 379.5% |
| Current ratio | 1.55x | 1.41x | 1.18x | 1.43x | 1.04x | 1.98x | 1.49x | 1.76x | 2.54x | 2.59x |
| Revenue YoY growth | 47.5% | -17.7% | -33.5% | 38.2% | -28.2% | -12.0% | 61.3% | 14.6% | 11706.3% | Unavailable |
| Net margin | -2.3% | -43.3% | -26.7% | -32.2% | Unavailable | -130.6% | -83.5% | -69.1% | -40.7% | -8843.5% |
| R&D / revenue | 26.4% | 23.5% | 32.4% | 44.4% | 69.9% | 74.2% | 96.4% | 140.1% | 127.4% | 7543.0% |
| CapEx / revenue | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 2.0% | 0.8% | 0.9% | 173.4% |
| Long-term debt / equity | 1.48x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AKBA in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2019-12-31
Difference 1880000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.